Kura Oncology Inc To Discuss Preliminary Combo Data Call Transcript
Good morning. My name is Krista, and I'll be your conference operator today. At this time, I would like to welcome everyone to the Kura Oncology virtual investor event. (Operator Instructions) Thank you. I would now like to turn the conference over to Troy Wilson, President and Chief Executive Officer of Oncology. Mr. Wilson, you may begin your conference.
Thank you, Krista, and good morning, everyone, and thank you for joining our call. I want to welcome you to our call to describe the preliminary clinical results from our KOMET-007 study. I'm here with my colleagues, Dr. Mollie Leoni and Dr. Stephen Dale. We're joined by Dr. Amir Zeidan and Dr. Amir Fathi as well, two investigators on the study. Each of them will take a turn in walking you through this set of slides.
If we turn now to slide number 3. We will be making on this call forward-looking statements. And I just want to draw your attention to our website, to the SEC website for more information about the risks and uncertainties in
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |